A NOVEL COMBINATION TO DEFEAT LIFE THREATENING ORGANISM PSEUDOMONAS AERUGINOSA
There is global increase in resistance among bacterial species that lead to critical infections. Most of the Gram-negative bacteria are labelled as multi drug resistant. Among all different species, the Pseudomonas aeruginosa (P.aeruginosa) is one of the leading causes of life-threatening infections...
Saved in:
Main Authors: | , , |
---|---|
Format: | Book |
Published: |
ziauddin University,
2019-04-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
MARC
LEADER | 00000 am a22000003u 4500 | ||
---|---|---|---|
001 | doaj_2ac48a6037d84d97a647a9219e1e4d3f | ||
042 | |a dc | ||
100 | 1 | 0 | |a Lubna Jahanzeb |e author |
700 | 1 | 0 | |a Zahida Memon |e author |
700 | 1 | 0 | |a M. Owais Ismail |e author |
245 | 0 | 0 | |a A NOVEL COMBINATION TO DEFEAT LIFE THREATENING ORGANISM PSEUDOMONAS AERUGINOSA |
260 | |b ziauddin University, |c 2019-04-01T00:00:00Z. | ||
500 | |a 2313-7371 | ||
500 | |a 2308-2593 | ||
520 | |a There is global increase in resistance among bacterial species that lead to critical infections. Most of the Gram-negative bacteria are labelled as multi drug resistant. Among all different species, the Pseudomonas aeruginosa (P.aeruginosa) is one of the leading causes of life-threatening infections. It has become difficult to treat P.aeruginosa infections in current scenario as antimicrobial resistance has increased against antimicrobial drugs. So it has become a challenge to select optimal antibacterial drug or regimen for the patient treatment to prevent further resistance. Ceftolozane/tazobactam (C/T) is a novel combination of broad spectrum antibacterial agents that is 5th generation cephalosporin antibiotic and β-lactamase inhibitor. It is considered a best choice for the treatment of complicated infections including ventilator-associated bacterial pneumonia, nosocomial pneumonia, urinary tract infections and intra-abdominal infections. Ceftolozane/tazobactam possess sensitivity of about >90% against β-lactam resistant strains of P.aeruginosa. This combination is superior to various other antibiotics and antibacterial regimen so it has initiated a new chapter in an era of complicated infections. This review appraises the comparison of different broad spectrum antibiotics like levofloxacin, meropenem and tobramycin and antibacterial combinations including tazobactam/cefepime, ceftazidime/avibactam, tazobactam/piperacillin, with the Ceftolozane/tazobactam combination. This article also evaluates the effect of C/T if given in combination with other drugs like daptomycin, metronidazole and amikacin. | ||
546 | |a EN | ||
690 | |a Critical infections | ||
690 | |a Multi drug resistant, P.aeruginosa | ||
690 | |a Ceftolozane/tazobactam | ||
690 | |a Biochemistry | ||
690 | |a QD415-436 | ||
690 | |a Dentistry | ||
690 | |a RK1-715 | ||
690 | |a Therapeutics. Pharmacology | ||
690 | |a RM1-950 | ||
690 | |a Medicine (General) | ||
690 | |a R5-920 | ||
655 | 7 | |a article |2 local | |
786 | 0 | |n Pakistan Journal of Medicine and Dentistry, Vol 7, Iss 2 (2019) | |
787 | 0 | |n https://ojs.zu.edu.pk/pjmd/article/view/180 | |
787 | 0 | |n https://doaj.org/toc/2313-7371 | |
787 | 0 | |n https://doaj.org/toc/2308-2593 | |
856 | 4 | 1 | |u https://doaj.org/article/2ac48a6037d84d97a647a9219e1e4d3f |z Connect to this object online. |